Reducing the non-FDA-approved use of antipsychotic drugs may be a way to save money while having little effect on patient care.

PITTSBURGH, April 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S.

PITTSBURGH, March 28, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S.

Physicians who prescribe antipsychotic medications may be basing their decisions on incomplete information.

A study in this week's PLoS Medicine suggests that the apparent clinical effectiveness of the newer form of drugs used to treat schizophrenia and other psychotic illnesses (second-generation anti-psychotic drugs) may be enhanced by the selective reporting of trials of these drugs in medical journals – a phenomenon called publication bias.